Please login to the form below

Not currently logged in
Email:
Password:

Trajenta

This page shows the latest Trajenta news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Boehringer already has an existing relationship with Yuhan, which acts as the South Korean marketer for three of the German firm’s Eli Lilly-partnered diabetes therapies, Tradjenta (linagliptin), Trajenta Duo

Latest news

More from news
Approximately 1 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Secondly, growth is ebbing away from Forxiga (dapagliflozin), the first entrant of the DPP4s, which is actually growing slightly slower than Trajenta. ... The key points here are that Trajenta is used by just under 8, 000 practices but appears to have

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    This includes Germany-based Boehringer Ingelheim's disapproval of the generic comparator used in IQWiG's AMNOG assessment of the diabetes medicine Trajenta (linagliptin).

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    The launch of Trajenta has been positive in many markets around the world. ... reimbursement body IQWIG refusing to recommend several new drugs, including Boehringer's diabetes treatment Trajenta.

  • A new dogma in HTA assessment A new dogma in HTA assessment

    Ingelheim and Eli Lilly's Type 2 diabetes drug Trajenta (linagliptin).

  • Country report: The healthcare market in Germany Country report: The healthcare market in Germany

    6. Less than comparator. It is significant that last year, BI and Lilly decided not to launch their new diabetes drug Trajenta in Germany, blaming price controls. ... Out of the 10 products assessed last year, four have obtained poor innovation scores:

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....